Sign In
Buy GILD
$125.05
+0.180 (+0.144%)
At Close: Jun 23, 2026
Gilead Sciences (GILD) Gains But Lags Market: What You Should Know
09:50pm, Wednesday, 13'th Apr 2022 Zacks Investment Research
Gilead Sciences (GILD) closed at $62.06 in the latest trading session, marking a +0.7% move from the prior day.
Gilead Sciences: The Most Undervalued Pharmaceutical Company
02:55pm, Wednesday, 13'th Apr 2022
According to my DCF analysis, GILD stock has a potential upside of almost 100%. After 7 years of stalemate, Gilead Sciences may be ready to reverse its downtrend.
Why Sierra Oncology Stock Is Soaring Today
12:14pm, Wednesday, 13'th Apr 2022 The Motley Fool
GlaxoSmithKline is adding another cancer asset to its portfolio by acquiring U.S.-based Sierra Oncology.
Gilead (GILD) Magrolimab Studies' Partial Clinical Hold Removed
03:20pm, Tuesday, 12'th Apr 2022 Zacks Investment Research
Gilead (GILD) studies evaluating its investigational agent magrolimab in combination with Vidaza are no longer under FDAs partial clinical hold.
Gilead (GILD) Magrolimab Studies' Partial Clinical Hold Removed
01:32pm, Tuesday, 12'th Apr 2022
Gilead (GILD) studies evaluating its investigational agent magrolimab in combination with Vidaza are no longer under FDAs partial clinical hold.
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Aeglea Shares Additional Phase 3 Data In Inherited Metabolic Disease
Aeglea BioTherapeutics Inc (NAS
RBC: the FDA lifting the hold on Gilead's experimental cancer therapy is a 'much-need piece of good news'
08:49am, Tuesday, 12'th Apr 2022
The Food and Drug Administration's decision on Monday to lift the partial hold on Gilead Sciences Inc.'s GILD, -0.66% magrolimab for two indications is "good news" for the company, according to RBC Ca
Gilead says FDA lifts partial clinical hold on MDS and AML magrolimab studies
08:50pm, Monday, 11'th Apr 2022 MarketWatch
The U.S. Food and Drug Administration has lifted a partial clinical hold on studies evaluating magrolimab in combination with azacitidine, Gilead Sciences Inc. said Monday.
Dow Jones Newswires: Gilead says FDA lifts partial clinical hold on MDS and AML magrolimab studies
04:50pm, Monday, 11'th Apr 2022
The U.S. Food and Drug Administration has lifted a partial clinical hold on studies evaluating magrolimab in combination with azacitidine, Gilead Sciences Inc. said Monday.
Dividend Income Update March 2022
03:31am, Monday, 11'th Apr 2022
The start of every month is exciting for all dividend income investors as we look back at the previous month and see how much passive dividend income our portfolios generated.
The Zacks Analyst Blog Highlights Bristol Myers, Vir Biotechnology, Gilead Sciences, and Vertex Pharmaceuticals
03:32pm, Friday, 08'th Apr 2022 Zacks Investment Research
Bristol Myers, Vir Biotechnology, Gilead Sciences, and Vertex Pharmaceuticals are part of top Analyst article.
Here's Why a Drop in Moderna's Revenue Wouldn't Be Catastrophic
12:00pm, Friday, 08'th Apr 2022 The Motley Fool
Moderna is preparing the terrain for more sales down the road.
Biotech Stock Roundup: VIR Down on Regulatory News, BMY Offers Updates & More
05:23pm, Thursday, 07'th Apr 2022 Zacks Investment Research
Regulatory and pipeline news from Vir Biotechnology (VIR) and Bristol Myers (BMY) are a few key highlights from the biotech sector during the past week.
Gilead Sciences: A Hindered Pipeline With Abundant Potential
07:14am, Thursday, 07'th Apr 2022
Gilead's HIV pipeline is the heart of the company's revenue stream, the other viral regimens not as much.
My Dividend Stock Portfolio: March 2022 Update - 101 Holdings And 29 Buys
05:30am, Thursday, 07'th Apr 2022 Seeking Alpha
The war in Ukraine continues to dominate market movements. Read why I am not selling and predominantly focusing on adding dividend income via select purchases.
